China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design

Authors

Liping Liu, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yilong Wang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xuewei Xie, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Dacheng Liu, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Aili Wang, Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Penglian Wang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Suwen Shen, Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Chongke Zhong, Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Yufei Wei, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Tan Xu, Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Yuesong Pan, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yong Jiang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xia Meng, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
David Wang, Neurovascular Division, Department of Neurology, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.Follow
Yonghong Zhang, Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, China.
Jiang He, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA yongjunwang@ncrcnd.org.cn jhe@tulane.edu.
Yongjun Wang, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China yongjunwang@ncrcnd.org.cn jhe@tulane.edu.

Document Type

Article

Abstract

BACKGROUNDS: Increased blood pressure (BP) for patients who had an acute ischaemic stroke is associated with poor functional outcome, however the optimal timing of antihypertensive therapy is unknown. AIMS: We aim to compare early antihypertensive treatment to delayed antihypertensive treatment for reducing the risk of composite major disability and mortality at 3 months in acute ischaemic stroke. DESIGN: The China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) trial is a multicentre, randomised, open-label, blinded-endpoints trial that will be conducted in 100 hospitals in China. The primary outcome is the composite of death and major disability (modified Rankin Scale score ≥3) at 3 months of randomisation. Antihypertensive treatment will be received immediately after randomisation in the early treatment group, aimed at average systolic BP by 10%-20% reduction within the first 24 hours, and achieving an average BP level of <140/90 mm Hg within 5 days. Patients in the delayed treatment group will discontinue any antihypertension medications for the first 7 days of randomisation, and will receive antihypertensive therapy achieving a BP goal of <140/90 mm Hg after 7 days. CONCLUSION: The CATIS-2 trial will be testing the hypotheses that early BP lowering leads to improved functional outcome without any other harms, and developing clinical guidelines of the BP management for patients who had an acute ischaemic stroke. TRIAL REGISTRATION NUMBER: NCT03479554.

Medical Subject Headings

Antihypertensive Agents (therapeutic use); Blood Pressure; Brain Ischemia (diagnosis, drug therapy); China; Humans; Ischemic Stroke (diagnosis, drug therapy); Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Time-to-Treatment; Treatment Outcome

Publication Date

6-1-2021

Publication Title

Stroke and vascular neurology

E-ISSN

2059-8696

Volume

6

Issue

2

First Page

286

Last Page

290

PubMed ID

33727409

Digital Object Identifier (DOI)

10.1136/svn-2020-000828

Recommended Citation

Liu, Liping; Wang, Yilong; Xie, Xuewei; Liu, Dacheng; Wang, Aili; Wang, Penglian; Shen, Suwen; Zhong, Chongke; Wei, Yufei; Xu, Tan; Pan, Yuesong; Jiang, Yong; Meng, Xia; Wang, David; Zhang, Yonghong; He, Jiang; and Wang, Yongjun, "China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design" (2021). Neurology. 1769.
https://scholar.barrowneuro.org/neurology/1769